dow theory forecasts posts
FeedPosted Mar 23rd 2011 12:40PM by Steven Halpern (RSS feed)
Filed under: Apple Inc (AAPL), Wal-Mart (WMT), Newsletters, International Business Machines (IBM), AFLAC Inc (AFL), Research in Motion (RIMM), Texas Instruments (TXN), Japan, Stocks to Buy
This post is part of Japan: A Special Report for Investors.
"Japan's tsunami has struck worldwide," says Richard Moroney, the editor of Dow Theory Forecasts, which has maintained a model portfolio of blue chip stocks for over 50 years.
Here, he reviews a number of the top buy recommendations in the newsletter's portfolios to determine the potential risk posed by the recent tragic developments in Japan.
Stocks cited as "Focus List Buys" are are those issues that the service expect to significantly outperform the market over the next 12 months.
Continue reading Japan: Dow Theory's Blue Chip Portfolio Review
Posted Feb 10th 2011 10:30AM by Steven Halpern (RSS feed)
Filed under: International Markets, Newsletters, Expedia Inc (EXPE), Commodities, Oil, Stocks to Buy
"On our proprietary Quadrix® rating system, ExxonMobil (XOM) has steadily advanced over the past year," says Richard Moroney.
The editor of Dow Theory Forecasts explains, "Out of a possible 100, the oil giant earns an Overall score of 96 -- compared to just 51 in January 2010. As such, we rate the stock a long-term buy.
"Meanwhile, the shares recently rallied to their highest level since January 2009 after Exxon said it earned $1.85 excluding special items in the December quarter, up 46% and $0.22 above the consensus estimate.
Continue reading Quantitative System Picks ExxonMobil (XOM)
Posted Jun 3rd 2010 1:30PM by Steven Halpern (RSS feed)
Filed under: International Markets, Newsletters, Newmont Mining (NEM), Commodities, Stocks to Buy
"While gold prices have surged 90% since year-end 2006, shares of Newmont Mining (NEM) still trade below their 2006 high of nearly $63 per share," observes Richard Moroney.
The editor of Dow Theory Forecasts, a blue-chip focused newsletter that has been published since 1946, explains, "Newmont generates more than 80% of its revenue from the sale \of gold, and the metal's recent strength has pushed earnings and cash flow sharply higher. As a result, the stock has seldom looked better under our "growth-at-a-good-price" approach.
Continue reading Newmont Mining (NEM): 'Growth at a Good Price'
Posted Apr 27th 2010 9:30AM by Nikhil Hutheesing (RSS feed)
Filed under: Newsletters, AFLAC Inc (AFL), CVS Corp (CVS), Oracle Corp (ORCL), Bargain Stocks, Stock Picks

At the beginning of a bull market, it's often the most speculative stocks that perform the best. As the market has rebounded over the past year, the Dow Jones Industrial Average (
$INDU) is up about 40% while the S&P SmallCap 600 Index is up about 58%. And that is exactly why Richard Moroney, editor of
Dow Theory Forecasts, is now sounding warning bells.
"The risk trade has defied conventional wisdom by continuing this year, tempting some investors to throw out their playbook and join the rush into high risk stocks," says Moroney
.
Moroney warns that investors chasing after risky companies will now be paying a premium for low quality merchandise. Instead, he suggests that investors pursue attractively valued stocks with good fundamentals.
Continue reading Guru Strategy: Don't Rush into Junk Stocks
Posted Nov 24th 2009 1:30PM by Steven Halpern (RSS feed)
Filed under: Baxter Intl (BAX), Stocks to Buy
"Baxter International (BAX) benefits from a robust balance sheet, solid operating momentum, and rising earnings estimates," says blue chip advisor Richard Moroney in Dow Theory Forecasts.
The advisor explains, "The first company to commercially prepare intravenous treatments, Baxter has manufactured and distributed medical products since 1931. It primarily works with blood and plasma, a business with recession-resistant tendencies.
"Its BioScience unit produces clotting agents for hemophilia and biotech drugs that treat both immune deficiencies and cancer.
Continue reading Baxter (BAX): Bank on blood products
Posted Sep 9th 2009 9:30AM by Steven Halpern (RSS feed)
Filed under: International Markets, Newsletters, Stocks to Buy, General Dynamics Corp (GD), Financial Crisis
"Investors considering high-yield stocks should consider financial strength; in our quantitative model, Quadrix, we assess profit margins, interest coverage, and debt levels," says Richard Moroney.
In Dow Theory Forecasts, a newsletter that has been published for over 5 decades -- he looks at two stocks that score high in this area: drug manufacturer, AstraZeneca (NYSE: AZN) and defense industry player, General Dynamics (NYSE: GD). Here, the advisor reviews the two companies.
"AstraZeneca's operating cash flow jumped 24% in the first half of 2009, allowing the company to retire $3 billion in debt since the end of 2008.
Continue reading AstraZeneca & General Dynamics: Financial strength
Next Page >